By the end of 2017, CTS has secured three source plasma partners and continues to seek additional partners in the plasma industry in order to continue to diversify CTS’s revenue stream.
In October, due to demand from existing healthcare partners, CTS began testing blood donors for anti...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...